Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Loading
Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Calendar quarter Q2 2026Earnings call Aug 5, 2026 · most recent call
CRL’s newest analyzed quarter is part of Tellvest Pro: its score, breakdown, narrative and analyst Q&A. Every prior quarter is free.
Sources. Scores: Charles River Laboratories’s public earnings-call transcripts and SEC-reported results — the base band is anchored to reported GAAP revenue growth; transcript, EPS and guidance adjustments are applied separately (documented exceptions apply to a few issuers). Price: CRL daily closing prices for the trailing year; dots mark earnings calls, colored by that quarter’s score; the newest quarter’s score is part of Tellvest Pro. How to read a company earnings-call score.
All prior quarters are free. How to browse earnings-call scores without Pro. How to read a company earnings-call score.
The breakdown for this quarter is part of Tellvest Pro.
Full Pro access for 30 days when you create a free account. No credit card required.
The table scrolls sideways. Swipe it, or select it and use the arrow keys.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $1.00B | -1.1% | $-4.22 | -216.6% | 28.4% | -16.7% | -21.5% | $84M |
| FY2025 Q1 | $984M | -2.7% | $0.50 | -61.5% | 32.3% | 7.6% | 2.6% | $112M |
| FY2025 Q2 | $1.03B | +0.6% | $1.06 | -39.1% | 34.6% | 9.7% | 5.1% | $169M |
| FY2025 Q3 | $1.00B | -0.5% | $1.10 | -17.3% | 33.7% | 13.3% | 5.4% | $178M |
| FY2025 Q4 | $994M | -0.8% | $-5.62 | -33.2% | 31.0% | 12.1% | -27.8% | $59M |
| FY2026 Q1 | $996M | +1.2% | $-0.30 | -160.0% | 28.0% | 12.0% | -1.5% | $-15M |
| FY2026 Q2Selected | $1.00B | -2.7% | $-0.03 | -102.8% | 36.2% | 11.9% | -0.1% | $149M |
Management-stated figures from CRL’s newest call are part of Tellvest Pro.
No 8-K events recorded since this call day.